Carboplatin (C) and docetaxel (D) in the second-line treatment of non-small cell lung cancer (NSCLC) patients pretreated with platinum-based regimens. A Phase II trial

被引：0
|
作者：
Numico, G
Buffoni, L
Dongiovanni, V
Schena, M
Fissore, C
Fea, E
Occelli, M
Colantonio, I
Merlano, M
Bertetto, O
机构：
[1] S Croce Gen Hosp, Cuneo, Italy
[2] S Giovanni Hosp, Turin, Italy
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)81035-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S260 / S260
页数：1
相关论文
共 50 条
  • [1] Carboplatin (C) and docetaxel (D) in second-line treatment of non-small cell lung cancer (NSCLC) patients (PTS) pretreated with platinum-based combinations (PBC): A phase II trial
    Buffoni, Lucio
    Fea, Elena
    Numico, Gianmauro
    Dongiovanni, Diego
    Barone, Carla
    Schena, Marina
    Colantonio, Ida
    Occelli, Marcella
    Mattiot, Valentina Polla
    Merlano, Marco
    ANNALS OF ONCOLOGY, 2007, 18 : 31 - 31
  • [2] A PHASE II STUDY OF DOCETAXEL MONOTHERAPY IN SECOND-LINE TREATMENT IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Reza, M. S.
    Hai, M. A.
    Chowdhury, Q.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 120
  • [3] Pilot study: Second-line carboplatin and docetaxel combination chemotherapy in the patients with advanced non-small-cell lung cancer(NSCLC) pretreated with cisplatin-based regimens.
    Park, SY
    Kim, KW
    Kim, MS
    Kim, SC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 692S - 692S
  • [4] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [5] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)
    Kayali, F.
    Janjua, M. A.
    Laber, D. A.
    Miller, D. M.
    Day, J. M.
    Kloecker, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial
    Nelli, F
    Naso, G
    Ceratti, ADP
    Saltarelli, R
    D'Auria, G
    Lugini, A
    Ferraldeschi, R
    Picone, V
    Moscetti, L
    Cortesi, E
    JOURNAL OF CHEMOTHERAPY, 2004, 16 (04) : 392 - 399
  • [7] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [8] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [9] A multicenter randomized phase II study of paclitaxel (P) and carboplatin (C) versus oral vinorelbine (oV) and carboplatin (C) as second-line treatment in patients (pts) with non-small cell lung cancer (NSCLC) pretreated with non-platinum based chemotherapy
    Agelaki, S.
    Syrigos, K.
    Polyzos, A.
    Agelidou, A.
    Handrinos, V
    Kotsakis, A.
    Christophyllakis, Ch
    Vardakis, N.
    Georgoulias, V
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S447 - S448
  • [10] Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer
    Laack, E
    Dierlamm, T
    Knuffmann, C
    Popp, J
    Schmied, B
    Dürk, H
    Wacker-Backerhaus, G
    Zeller, W
    Verpoort, K
    Fiedler, W
    Hossfeld, DK
    LUNG CANCER, 2002, 36 (03) : 303 - 307
12345